Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Blood

Volumn 130, Issue 6, 2017, Pages 722-731

  Stein, Eytan M ^a,b   DiNardo, Courtney D ^c   Pollyea, Daniel A ^d   Fathi, Amir T ^e,f   Roboz, Gail J ^b,g   Altman, Jessica K ^h   Stone, Richard M ⁱ   Deangelo, Daniel J ⁱ   Levine, Ross L ^a   Flinn, Ian W ^j   Kantarjian, Hagop M ^c   Collins, Robert ^k   Patel, Manish R ^l   Frankel, Arthur E ^k   Stein, Anthony ^m   Sekeres, Mikkael A ⁿ   Swords, Ronan T ^o   Medeiros, Bruno C ^p   Willekens, Christophe ^q,r   Vyas, Paresh ^s,t   Tosolini, Alessandra ^u   Xu, Qiang ^u   Knight, Robert D ^u   Yen, Katharine E ^v   Agresta, Sam ^v   De Botton, Stephane ^q,r   Tallman, Martin S ^a,b   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j SARAH CANNON RESEARCH INSTITUTE   (United States)

^k UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^l Florida Cancer Specialists   (United States)

^m CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

ⁿ TAUSSIG CANCER INSTITUTE   (United States)

^o UNIVERSITY OF MIAMI   (United States)

^p STANFORD CANCER INSTITUTE   (United States)

^q INSTITUT GUSTAVE ROUSSY   (France)

^r UNIVERSITÉ PARIS SACLAY   (France)

^s UNIVERSITY OF OXFORD   (United Kingdom)

^t OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^u CELGENE CORPORATION   (United States)

^v AGIOS PHARMACEUTICALS   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CD135 ANTIGEN; CORTICOSTEROID; ENASIDENIB; ISOCITRATE DEHYDROGENASE 2; NUCLEOPHOSMIN; TRIACYLGLYCEROL LIPASE; AG-221; AMINOPYRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; TRIAZINE DERIVATIVE;

ACUTE MYELOID LEUKEMIA; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER MORTALITY; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL MATURATION; CONCENTRATION AT STEADY-STATE; CORTICOSTEROID THERAPY; DECREASED APPETITE; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FATIGUE; FEMALE; FIRST IN HUMAN STUDY; FOLLOW UP; GENE MUTATION; HUMAN; HYPERBILIRUBINEMIA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY RATE; MULTIPLE CYCLE TREATMENT; MYELOBLAST; NAUSEA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RETINOIC ACID SYNDROME; SIDE EFFECT; SYSTEMIC THERAPY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT INTERRUPTION; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR LYSIS SYNDROME; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; BONE MARROW; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MUTATION; PATHOLOGY; TUMOR RECURRENCE; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AMINOPYRIDINES; ANTINEOPLASTIC AGENTS; BONE MARROW; ENZYME INHIBITORS; FEMALE; HUMANS; ISOCITRATE DEHYDROGENASE; LEUKEMIA, MYELOID, ACUTE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; TRIAZINES; YOUNG ADULT;

EID: 85028038117     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-04-779405     Document Type: Article

References (37)

1. Walter RB, Estey EH. Management of older or unfit patients with acute myeloid leukemia. Leukemia. 2015;29(4):770-775.
2. Rosenblat TL, McDevitt MR, Mulford DA, et al. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res. 2010;16(21):5303-5311.
3. Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97(12):1916-1924.
4. DiNardo CD, Jabbour E, Ravandi F, et al. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia. 2016;30(4):980-984.
5. Medeiros BC, Fathi AT, DiNardo CD, Pollyea DA, Chan SM, Swords R. Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia. 2017;31(2):272-281.
6. DiNardo CD, Ravandi F, Agresta S, et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol. 2015;90(8):732-736.
7. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17(3): 225-234.
8. Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28(14): 2348-2355.
9. Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010;28(22):3636-3643.
10. Abbas S, Lugthart S, Kavelaars FG, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood. 2010;116(12): 2122-2126.
11. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553-567.
12. Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012; 483(7390):474-478.
13. Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of a-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1):17-30.
14. Kats LM, Reschke M, Taulli R, et al. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell. 2014; 14(3):329-341.
15. Fathi AT, Sadrzadeh H, Borger DR, et al. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood. 2012;120(23):4649-4652.
16. DiNardo CD, Propert KJ, Loren AW, et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood. 2013;121(24): 4917-4924.
17. Janin M, Mylonas E, Saada V, et al. Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol. 2014;32(4):297-305.
18. Fan B, Chen Y, Wang F, et al. Pharmacokinetic/ pharmacodynamic (PK/PD) evaluation of AG-221, a potent mutant IDH2 inhibitor, from a phase 1 trial of patients with IDH2 mutation-positive hematologic malignancies [abstract]. Haematologica. 2015;100. Abstract 379.
19. Shih AH, Shank KR, Meydan C, et al. AG-221, a small molecule mutant IDH2 inhibitor, remodels the epigenetic state of IDH2-mutant cells and induces alterations in self-renewal/differentiation in IDH2-mutant AML model in vivo [abstract]. Blood. 2014;124(21). Abstract 437.
20. Yen K, Travins J, Wang F, et al. AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations. Cancer Discov. 2017;7(5):478-493.
21. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
22. Cheson BD, Bennett JM, Kopecky KJ, et al; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21(24):4642-4649.
23. Clinical Practice Guidelines in Oncology. Acute Myeloid Leukemia, version 1.2017. http://www.nccn.org/professionals/physician_gls/ f_guidelines.asp. Accessed 7 March 2017.
24. Wang F, Travins J, DeLaBarre B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 2013;340(6132): 622-626.
25. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12): 1136-1152.
26. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670-2677.
27. Hämäläinen S, Kuittinen T, Matinlauri I, Nousiainen T, Koivula I, Jantunen E. Neutropenic fever and severe sepsis in adult acute myeloid leukemia (AML) patients receiving intensive chemotherapy: Causes and consequences. Leuk Lymphoma. 2008;49(3):495-501.
28. Walter RB, Taylor LR, Gardner KM, Dorcy KS, Vaughn JE, Estey EH. Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia. Clin Adv Hematol Oncol. 2013;11(9):571-577.
29. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232.
30. Zuckerman T, Ganzel C, Tallman MS, Rowe JM. How I treat hematologic emergencies in adults with acute leukemia. Blood. 2012;120(10): 1993-2002.
31. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337(15): 1021-1028.
32. Baljevic M, Park JH, Stein E, Douer D, Altman JK, Tallman MS. Curing all patients with acute promyelocytic leukemia: are we there yet? Hematol Oncol Clin North Am. 2011;25(6): 1215-1233.
33. Birendra KC, DiNardo CD. Evidence for clinical differentiation and differentiation syndrome in patients with acute myeloid leukemia and IDH1 mutations treated with the targeted mutant IDH1 inhibitor, AG-120. Clin Lymphoma Myeloma Leuk. 2016;16(8):460-465.
34. Sanz MA, Montesinos P. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood. 2014; 123(18):2777-2782.
35. Nazha A, Sekeres MA, Garcia-Manero G, et al; MDS Clinical Research Consortium. Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. Leuk Res. 2016;41: 43-47.
36. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447.
37. Roboz GJ, Rosenblat T, Arellano M, et al. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. J Clin Oncol. 2014;32(18):1919-1926.